Clinical pharmacokinetics of amfetamine and related substances -: Monitoring in conventional and non-conventional matrices

被引:102
作者
de la Torre, R
Farré, M
Navarro, M
Pacifici, R
Zuccaro, P
Pichini, S
机构
[1] Ist Super Sanita, Dept Drug Res & Control, I-00161 Rome, Italy
[2] Inst Municipal Invest Med, Pharmacol Unit, E-08003 Barcelona, Spain
[3] Univ Pompeu Fabra, Barcelona, Spain
[4] Univ Autonoma Barcelona, E-08193 Barcelona, Spain
关键词
D O I
10.2165/00003088-200443030-00002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Consumption of amfetamine-type stimulants, including classical amfetamines and 'designer drugs', has been recognised as one of the most significant trends in drug abuse at the end of the past century and at the beginning of the current one. The first cause is the increasing consumption amongst youth of methylenedioxy and methoxy-substituted amfetamines, of which the pharmacology in humans is currently under investigation. Secondly, the abuse of more classical amfetamines, such as amfetamine itself and metamfetamine, continues to be highly prevalent in some geographical regions. Amfetamines are powerful psychostimulants, producing increased alertness, wakefulness, insomnia, energy and self-confidence in association with decreased fatigue and appetite as well as enhanced mood, well-being and euphoria. From a clinical pharmacokinetic perspective, amfetamine-type stimulants are rather homogeneous. Their oral bioavailability is good, with a high distribution volume (4 L/kg) and low binding to plasma proteins (less than 20%). The elimination half-life is 6-12 hours. Both hepatic and renal clearance contribute to their elimination from the body. Hepatic metabolism is extensive in most cases, but a significant percentage of the drug always remains unaltered. Amfetamine and related compounds are weak bases, with a pKa around 9.9, and a relatively low molecular weight. These characteristics allow amfetamine-type stimulants to diffuse easily across cell membranes and lipid layers and to those tissues or biological substrates with a more acidic pH than blood, facilitating their detection in alternative matrices at relatively high concentrations. In most cases, the concentrations found are higher than expected from the Henderson-Hasselbach equation. Drug monitoring in non-conventional biological matrices (e.g. saliva, hair, nails, sweat) has recently gained much attention because of its possible applications in clinical and forensic toxicology. An individual's past history of medication, compliance or drug abuse can be obtained from testing of hair and nails, whereas data on current status of drug use can be provided by analysis of sweat and saliva. Because of the physicochemical properties of amfetamine-type stimulants, this group of drugs is one of the most suitable for drug testing in non-conventional matrices.
引用
收藏
页码:157 / 185
页数:29
相关论文
共 202 条
[1]  
ANGGARD E, 1973, CLIN PHARMACOL THER, V14, P870
[2]  
ANGGARD E, 1970, ACTA PHARMACOL TOX, V28, P92
[3]  
ANGGARD E, 1977, DRUG ADDICTION, V2, P6
[4]   EARLY PHARMACOKINETICS AND CLINICAL EFFECTS OF ORAL D-AMPHETAMINE IN NORMAL SUBJECTS [J].
ANGRIST, B ;
CORWIN, J ;
BARTLIK, B ;
COOPER, T .
BIOLOGICAL PSYCHIATRY, 1987, 22 (11) :1357-1368
[5]  
[Anonymous], 2001, ECSTASY COMPLETE GUI
[6]  
[Anonymous], 1995, DISPOSITION TOXIC DR
[7]   Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives [J].
Bach, MV ;
Coutts, RT ;
Baker, GB .
XENOBIOTICA, 1999, 29 (07) :719-732
[8]   Metabolism of N,N-dialkylated amphetamines, including deprenyl, by CYP2D6 expressed in a human cell line [J].
Bach, MV ;
Coutts, RT ;
Baker, GB .
XENOBIOTICA, 2000, 30 (03) :297-306
[9]   Metabolic production of amphetamine following multidose administration of clobenzorex [J].
Baden, KL ;
Valtier, S ;
Cody, JT .
JOURNAL OF ANALYTICAL TOXICOLOGY, 1999, 23 (06) :511-517
[10]   Chemical analysis of ecstasy pills [J].
Baggott, M ;
Heifets, B ;
Jones, RT ;
Mendelson, J ;
Sferios, E ;
Zehnder, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (17) :2190-2190